close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

9.160 +0.110 (+1.22%)
Official Closing Price Updated: 7:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Organon & Co. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
3 Small-Cap Stocks We Steer Clear Of
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
1 Profitable Stock Worth Your Attention and 2 Facing Challenges
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
DexCom, Masimo, Integer Holdings, The Pennant Group, and Organon Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
Q2 Earnings Highs And Lows: Organon (NYSE:OGN) Vs The Rest Of The Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Earnings Scheduled For August 5, 2025
 
Via Benzinga
A Look Ahead: Organon's Earnings Forecast
 
Via Benzinga
3 Reasons to Avoid OGN and 1 Stock to Buy Instead
Over the past six months, Organon’s shares (currently trading at $11.05) have posted a disappointing 11.7% loss, well below the S&P 500’s 32.7% gain. This may have investors wondering how to approach... 
Via StockStory
Topics Government Stocks World Trade
Healthcare Staffing Giant AMN Healthcare Soars Amidst Landmark Drug-Pricing Agreement
New York, NY – September 30, 2025 – AMN Healthcare Services (NYSE: AMN), a leading provider of healthcare staffing solutions, witnessed a significant upward movement in its stock today, reflecting a... 
Via MarketMinute
Topics Government
Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing... 
Via MarketMinute
Topics Economy Government World Trade
AbbVie, AMN Healthcare Services, LeMaitre, Waters Corporation, and Organon Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. 
Via StockStory
Topics Government
1 Surging Stock Worth Your Attention and 2 We Avoid
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage... 
Via StockStory
Topics Initial Public Offering
Johnson & Johnson's Hypothetical Rally: A Look at Potential 2025 Valuation Drivers
In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and... 
Via MarketMinute
Topics Economy Intellectual Property
Why Organon (OGN) Stock Is Trading Up Today
Shares of pharmaceutical company Organon (NYSE:OGN) jumped 2.1% in the morning session after the stock extended its positive momentum as the U.S. Food and Drug Administration (FDA) approved its two... 
Via StockStory
Topics Artificial Intelligence Economy Initial Public Offering
3 Stocks Under $50 We Find Risky
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
3 Cash-Producing Stocks with Warning Signs
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
1 Healthcare Stock Worth Investigating and 2 Facing Challenges
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID... 
Via StockStory
Topics Stocks
Brookdale, Evolent Health, Fortrea, 10x Genomics, and Organon Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Artificial Intelligence Economy
OGN Q2 Deep Dive: Flat Sales, Margin Pressure, and Strategic Shifts Highlight Quarter
Pharmaceutical company Organon (NYSE:OGN) beat Wall Street’s revenue expectations in Q2 CY2025, but sales were flat year on year at $1.59 billion. The company expects the full year’s revenue to be... 
Via StockStory
3 of Wall Street’s Favorite Stocks We Find Risky
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Organon (OGN) Fiscal Q2 Revenue Beats 1%
Via The Motley Fool
Organon (NYSE:OGN) Surprises With Q2 Sales, Stock Soars
Pharmaceutical company Organon (NYSE:OGN) reported Q2 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $1.59 billion. The company expects the full year’s... 
Via StockStory
Organon Earnings: What To Look For From OGN
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings this Tuesday before market hours. Here’s what you need to know. 
Via StockStory
Unpacking Q1 Earnings: Organon (NYSE:OGN) In The Context Of Other Branded Pharmaceuticals Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 Stocks Under $50 in the Doghouse
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
Organon Drops Drug Development For Endometriosis Pain After Mid-Stage Study Fails To Show Results
Organon said that the mid-stage study evaluating its OG-6219 in endometriosis-related pain did not demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to... 
Via Stocktwits
2 Cash-Producing Stocks for Long-Term Investors and 1 to Think Twice About
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
1 Profitable Stock for Long-Term Investors and 2 to Be Wary Of
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Easy Income Portfolio: June 2025 Update
 
Via Benzinga
3 of Wall Street’s Favorite Stocks in Hot Water
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
3 Small-Cap Stocks Walking a Fine Line
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today